Viking Therapeutics, Inc.VKTXNASDAQ
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-87.79M
↓ 146% below average
Average (9y)
$-35.70M
Historical baseline
Range
High:$-8.73M
Low:$-87.79M
CAGR
+29.2%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-87.79M | -19.6% |
| 2023 | $-73.38M | -51.6% |
| 2022 | $-48.40M | -1.7% |
| 2021 | $-47.59M | -118.5% |
| 2020 | $-21.78M | +12.0% |
| 2019 | $-24.75M | -32.0% |
| 2018 | $-18.75M | -27.1% |
| 2017 | $-14.76M | -33.3% |
| 2016 | $-11.07M | -26.8% |
| 2015 | $-8.73M | - |